BEDSIDE ACTION BOX — Preventing & Detecting IVH
- Prevention is everything in the first 72 hours: delayed cord clamping, midline head positioning, minimal handling, gentle ventilation, and avoiding rapid swings in blood pressure, CO₂, and osmolarity.
- Screen all <33-week / <1500 g infants with cranial ultrasound on the network schedule; scan sooner after any major event (collapse, NEC, unexplained Hb drop, neurological change).
- Grade I–IV by whether the ventricle is dilated (section 4); grade III–IV carries the worst prognosis.
- After significant IVH, watch for post-haemorrhagic ventricular dilatation with serial head circumference, ventricular index, and clinical signs.
- Avoid routine rapid volume boluses, hyperosmolar agents (e.g., sodium bicarbonate), and hypocapnia — all increase IVH risk.
1. Overview & Definition
Overview
Germinal matrix–intraventricular haemorrhage (IVH) is the most common serious neurological complication of prematurity. It arises from the fragile, highly vascular germinal matrix, which is vulnerable to fluctuations in cerebral blood flow, and typically occurs in the first 72 hours of life. Most IVH is clinically silent and detected on screening ultrasound; the priorities are prevention, systematic screening, accurate grading, and vigilance for post-haemorrhagic ventricular dilatation (PHVD).
Why This Topic Matters
Higher-grade IVH (III–IV) is strongly associated with cerebral palsy, cognitive impairment, and hydrocephalus. Because there is no cure once bleeding occurs, the greatest impact comes from prevention bundles and from early recognition of progressive ventricular dilatation, where timely intervention can preserve outcome.
Definition
IVH is bleeding originating in the subependymal germinal matrix that may extend into the ventricular system and, at its most severe, into the periventricular parenchyma (periventricular haemorrhagic infarction). PHVD is progressive ventricular enlargement following IVH, which may become symptomatic post-haemorrhagic hydrocephalus requiring drainage.
2. Who This Guideline Applies To
Scope
- Preterm infants at risk of IVH: gestation <33 weeks, birth weight <1500 g, ventilated, abnormal neurology or clotting, and other high-risk features.
- Infants with detected IVH requiring grading, monitoring, and surveillance for PHVD.
- Term/near-term infants with intracranial haemorrhage from other mechanisms are assessed differently (imaging-led) — cross-reference HIE (9.1), seizures (9.3), and the bleeding neonate (10.3).
3. Key Definitions
Core Terminology
The vocabulary of germinal-matrix haemorrhage and its complications.
| Term | Definition | Practical note |
|---|
| Germinal matrix | Fragile, highly vascular subependymal region in the preterm brain. | Origin of IVH; involutes with maturity. |
| IVH | Haemorrhage into the germinal matrix ± ventricles ± parenchyma. | Graded I–IV (section 4). |
| PVHI | Periventricular haemorrhagic infarction (parenchymal involvement). | Formerly "grade IV"; worst prognosis; usually unilateral. |
| PHVD | Post-haemorrhagic ventricular dilatation. | Track with ventricular index and head circumference. |
| Ventricular index | Ultrasound measure of ventricular width (plotted on Levene charts). | Serial trend guides intervention. |
4. Grading
IVH Grades (Baylor Ed. 33)
Grade by ultrasound appearance; higher grades and parenchymal involvement predict worse neurodevelopmental outcome.
| Grade | Ultrasound finding | Prognostic note |
|---|
| I | Haemorrhage confined to the germinal matrix. | Generally favourable. |
| II | IVH without ventricular dilatation, whatever the volume of blood. | Usually good; monitor. |
| III | IVH with ventricular dilatation. | Higher risk of PHVD and impairment. |
| IV (PVHI) | Parenchymal (periventricular) haemorrhagic infarction, typically unilateral. | Worst prognosis; ~90% of survivors have significant neurodevelopmental sequelae. |
Terminology Note
"Grade IV" is a parenchymal venous infarction adjacent to a large IVH, not simply "more blood in the ventricle." Report the grade, laterality, presence/degree of ventricular dilatation, and any parenchymal lesion, and compare with prior scans.
The epidemiology, and why screening is routine (Baylor Ed. 33)
- Roughly 28% of all VLBW infants are affected, and the overall frequency has not fallen over the past decade. Severity runs inversely with gestation and weight: 40% of infants born at 500–750 g against 20% at 1001–1250 g.
- About 50% occur within the first postnatal day and virtually all within the first week — which is what sets the screening timetable.
- Most affected infants are asymptomatic, which is the whole reason cranial ultrasound screening is routine rather than symptom-driven.
- Where it starts: the subependymal germinal matrix, a primitive vascular network most prominent between 28 and 34 weeks that has involuted by term. The pathogenesis combines intravascular factors (fluctuating blood pressure, swings in cerebral blood flow, raised cerebral venous pressure, platelet and coagulation disturbance), vascular fragility of that bed and its vulnerability to hypoxic-ischaemic injury, and extravascular excessive fibrinolytic activity within the matrix itself.
5. Cranial Ultrasound Screening
Who to Screen
Gestation <33 weeks, birth weight <1500 g, ventilated infants, abnormal neurology, abnormal clotting, congenital/dysmorphic features or suspected cranial malformation, and micro/macrocephaly.
Minimum Screening Schedule
A representative network schedule — follow your unit's protocol; add scans after any significant clinical event.
| Gestation | Scan timing |
|---|
| <30 weeks | Days 0–3, days 6–10, days 14–16, then 36 weeks' CGA or at discharge. |
| 30–32 weeks | Days 3–7, then 36 weeks' CGA or at discharge. |
| Additional scans (any gestation) | After NEC, major collapse, severe recurrent apnoea/bradycardia, unexplained Hb fall, neurological change, abnormal head growth, or peri-operatively; serial scans if abnormality found (consultant-directed). |
6. Prevention (Highest Yield)
IVH-Prevention Bundle
- Antenatal: antenatal corticosteroids; antenatal magnesium sulphate for neuroprotection; deliver at/transfer to an appropriate-level centre before birth.
- Delivery room: delayed cord clamping when safe (avoid cord milking <28 weeks); gentle resuscitation; maintain normothermia.
- First 72 hours ("golden hours"): minimal handling, midline neutral head position, cluster care, and avoid rapid changes in blood pressure, PaCO₂ (avoid both hyper- and hypocapnia), and serum osmolarity.
- Avoid rapid volume boluses and hyperosmolar agents (e.g., sodium bicarbonate); treat a haemodynamically significant PDA thoughtfully; correct coagulopathy.
- Caffeine and careful ventilation (avoid pneumothorax and large tidal-volume swings).
7. Management Algorithm
1
Prevent (antenatal → first 72 h)
Antenatal steroids/magnesium, DCC, minimal handling, midline positioning, stable BP/CO₂/osmolarity, avoid rapid boluses and hyperosmolar agents.
2
Screen on schedule
Cranial ultrasound per gestation-based schedule; scan sooner after any significant event or neurological change.
3
IVH detected?
Grade (I–IV), note laterality, ventricular size, and any parenchymal lesion; correct coagulopathy/anaemia; optimise haemodynamics; document and inform parents.
4
Grade III–IV or any dilatation?
Increase surveillance: serial ultrasound with ventricular index, daily-to-alternate-day head circumference, and clinical signs of raised pressure. Involve neurosurgery early for progressive PHVD.
5
Progressive PHVD?
Follow the network PHVD pathway (thresholds by ventricular index/rate of change and symptoms): temporising CSF drainage (ventricular reservoir/tap or external drain) and, later, definitive shunt/ETV as indicated. (See caution below on drugs.)
6
⚠ Do-not-miss
Rapidly increasing head circumference, tense fontanelle, sutural splaying, apnoea/bradycardia, sunsetting eyes, or falling conscious level = raised intracranial pressure — urgent imaging and neurosurgical referral.
8. Post-Haemorrhagic Ventricular Dilatation (PHVD)
Recognition & Monitoring
- Follow serial ultrasound measurements (ventricular index at the level of the third ventricle/foramen of Munro, plotted on reference charts), daily-to-alternate-day head circumference, and fontanelle/suture examination.
- Distinguish stable/arrested dilatation from progressive dilatation with rising pressure — the trajectory drives management.
Intervention (Network/Neurosurgery-Led)
- Progressive PHVD reaching network thresholds is managed with CSF removal — temporising measures (lumbar punctures where communicating, ventricular reservoir with intermittent taps, or an external ventricular drain) followed by a definitive ventriculoperitoneal shunt or endoscopic third ventriculostomy when the infant is large/stable enough.
- Timing and thresholds vary by network (e.g., "early" intervention approaches such as DRIFT are specialist-led); follow local neurosurgical protocol.
Not Effective / Not Recommended
Acetazolamide plus furosemide is not recommended to treat PHVD (no benefit and potential harm). Serial lumbar punctures do not prevent shunt dependence and are used only as a temporising measure in communicating dilatation. Management is fundamentally surgical/CSF-diversion, not pharmacological.
9. Monitoring
Monitoring Table
Surveillance after IVH detection and during PHVD follow-up.
| Parameter | Frequency | Target / watch | Action if abnormal |
|---|
| Cranial ultrasound | Per schedule; more often if IVH/PHVD | Stable ventricular size | Increasing dilatation → neurosurgery. |
| Head circumference | Daily–alternate days if PHVD | Growth along centile | Rapid crossing of centiles → urgent review. |
| Ventricular index | With each scan if dilated | Below intervention threshold | Rising trend → CSF diversion pathway. |
| Fontanelle / sutures / neuro | Each exam | Soft fontanelle, stable neurology | Tense fontanelle/apnoea → raised ICP workup. |
| Haemoglobin / coagulation | As indicated | Corrected | Transfuse/correct; investigate unexplained drops. |
10. Contraindications & Precautions
Safety Cautions
- Avoid rapid volume boluses and hyperosmolar agents (e.g., sodium bicarbonate), especially in the first 72 hours — they increase IVH risk.
- Avoid hypocapnia and hypercapnia and large swings in blood pressure and oxygenation.
- Avoid umbilical cord milking below 28 weeks (IVH risk).
- Do not rely on acetazolamide/furosemide or repeated lumbar punctures to prevent shunt dependence in PHVD.
- Do not miss evolving raised intracranial pressure — escalate promptly.
11. Escalation & Follow-Up
Escalate When…
- Grade III–IV IVH, any progressive ventricular dilatation, or clinical signs of raised intracranial pressure — refer to neurosurgery early.
- Rapidly increasing head circumference or new neurological deterioration.
- Uncertainty in grading or measurement — senior/neuroradiology review.
Follow-Up
- Structured neurodevelopmental follow-up (motor, cognitive, vision, hearing) — risk rises with grade and PVHI.
- Ongoing head-growth and ventricular surveillance after discharge for those with dilatation or shunts.
- Early-intervention/physiotherapy referral for higher-grade IVH/PVHI.
Parent Counselling Points
- "Babies born very early can bleed into a fragile area of the brain. Most small bleeds cause no lasting problems; larger bleeds carry more risk, which we monitor closely with head scans."
- "We watch the fluid spaces in the brain with regular scans and head measurements. If the fluid builds up, we work with neurosurgeons to relieve the pressure."
- "We will arrange developmental follow-up so any needs are picked up and supported early."
12. Key Pearls
High-Value Clinical Pearls
- Most IVH is silent and occurs in the first 72 hours — prevention and scheduled screening matter more than symptoms.
- The prevention bundle (antenatal steroids/magnesium, DCC, minimal handling, midline head, stable physiology) is the best "treatment."
- "Grade IV" is a parenchymal venous infarction (PVHI), not just a big IVH — report it precisely.
- Track PHVD with ventricular index and head circumference trends, not a single measurement.
- PHVD is managed by CSF diversion/neurosurgery — acetazolamide/furosemide don't work.
- Rising head circumference + tense fontanelle + apnoea = raised ICP: act now.
13. Common Mistakes to Avoid
Pitfalls & Better Practice
The recurring errors in IVH prevention and PHVD care.
| Mistake | Why it harms | Better practice |
|---|
| Rapid boluses / bicarbonate in the first days. | Increases IVH risk. | Cautious, slow fluids; avoid hyperosmolar agents. |
| Cord milking <28 weeks. | Associated with severe IVH. | Use delayed cord clamping instead. |
| Missing the screening window. | Undetected significant IVH/PHVD. | Follow gestation-based schedule; scan after events. |
| Treating PHVD with acetazolamide/furosemide. | No benefit, potential harm. | CSF diversion / neurosurgical pathway. |
| Acting on a single ventricular measurement. | Misjudges trajectory. | Use serial trends (index + HC). |
| Delaying neurosurgical referral. | Progressive hydrocephalus/injury. | Refer early for grade III–IV or progressive PHVD. |
14. Board-Style High-Yield Summary
Key Takeaways
- IVH originates in the germinal matrix, usually in the first 72 hours; risk rises with decreasing gestation.
- Grades: I germinal matrix only; II IVH without ventricular dilatation; III IVH with dilatation; IV parenchymal haemorrhagic infarction (worst).
- Screen <33 wk / <1500 g by cranial ultrasound on the network schedule; scan after significant events.
- Prevention bundle: antenatal steroids/magnesium, DCC (no cord milking <28 wk), minimal handling, midline head, stable BP/CO₂/osmolarity, avoid rapid boluses/bicarbonate.
- Monitor PHVD with ventricular index + head circumference trends; manage progressive dilatation with CSF diversion/neurosurgery.
- Acetazolamide/furosemide are not recommended for PHVD.
15. References
- 1.Bedside Clinical Guidelines Partnership / West Midlands Neonatal ODN. Cranial Ultrasound Scans; Post-Haemorrhagic Ventricular Dilatation. Neonatal Guidelines 2025–28.
- 2.Papile LA, et al. Incidence and evolution of subependymal and intraventricular hemorrhage. J Pediatr. 1978;92:529–534.
- 3.Volpe JJ. Volpe's Neurology of the Newborn, 6th ed. (germinal matrix–IVH; PVHI).
- 4.Whitelaw A, et al. Management of post-haemorrhagic ventricular dilatation; DRIFT trial. Cochrane Database Syst Rev / Pediatrics.
- 5.Baylor College of Medicine, Division of Neonatology. Guidelines for Acute Care of the Neonate, Edition 33, 2025–2026.
- 6.Antenatal magnesium sulphate for neuroprotection (Cochrane; national guidance). https://www.cochranelibrary.com/
Back to Clinical Guideline Hubs